Eli Lilly

Zealand Pharma

Altimmune

Amgen

Rogers

Viking Therapeutics

Pfizer

Terns Pharmaceuticals

Regeneron Pharmaceuticals

Rhythm Pharmaceuticals

Roundhill GLP-1 & Weight Loss ETF

OZEM is an actively managed fund that invests in companies from around the world involved in pharmaceutical drugs and supplements used for weight management.

Fidelity MSCI Consumer Staples ETF

Tema Obesity & Cardiometabolic ETF

iShares U.S. Pharmaceuticals ETF

iShares U.S. Aerospace & Defense ETF

iShares U.S. Healthcare ETF

iShares U.S. Consumer Goods ETF

Invesco Dynamic Pharmaceuticals ETF

Invesco Aerospace & Defense ETF

VanEck Vectors Pharmaceutical ETF

Global X Defense Tech ETF

Amplify Weight Loss Drug & Treatment ETF

Vanguard Consumer Staples ETF

Vanguard Utilities ETF

SPDR S&P Aerospace & Defense ETF

Consumer Staples Select Sector SPDR Fund

Utilities Select Sector SPDR Fund

Health Care Select Sector SPDR Fund

When markets correct, it is a good time to revisit which equity market sectors are “defensive” themes. Certain products and services are nondiscretionary in nature that we cannot live without.

Disruptive Theme of the Week: Playing Defense

Two companies, Eli Lilly (LLY) and Novo Nordisk (NVO), have so far dominated the weight-loss drug market. Now, Roche recently announced encouraging Phase I trial data for its new obesity drug candidate.

ETFs in Focus as Competition Heats Up in Weight Loss Drug Segment

ProShares Ultra Silver

Amplify Transformational Data Sharing ETF

Sonicshares Global Shipping ETF

First Trust SkyBridge Crypto Industry and Digital Economy ETF

GraniteShares 1.5x Long NVDA Daily ETF

Direxion Daily NVDA Bull 1.5X Shares

US Global Sea to Sky Cargo ETF

Strive US Semiconductor ETF

Global X Silver Miners ETF

Amplify Junior Silver Miners ETF

Aberdeen Standard Physical Silver Shares ETF

iShares Silver Trust

iShares MSCI Global Silver Miners ETF

VanEck Vectors Semiconductor ETF

Invesco PHLX Semiconductor ETF

iShares PHLX Semiconductor ETF

After a torrid risk-on run in the first quarter of 2024, markets cooled off a bit but ended the half still positive with mid-double-digit returns. Technology themes such as cryptocurrency and artificial intelligence helped propel markets higher.

Top Themes in the First Half of 2024: Crypto, Chips, Ships & Silver

Two new weight-loss exchange-traded funds (ETFs) launched in May have yet to whet investors' appetite, possibly due to their expensive fees and concentrated bets.

Why Investors Haven't Feasted on Two New Weight-Loss ETFs

As weight loss drugs are gaining popularity a new way to invest in the companies behind these products has launched with the Roundhill GLP 1 And Weight Loss ETF (NASDAQ:OZEM). Let's get into everything investors need to know about this new weight loss exchange-traded fund (ETF) before investing in OZEM stock below!

OZEM ETF: 7 Things to Know About the New Roundhill GLP-1 & Weight Loss ETF

While Novo Nordisk and Eli Lilly have soared in the past year, Roundhill Investments sees bigger gains ahead for the GLP-1 drugmakers.

This new weight loss drug ETF bets big on two of the industry's leading players

J.P. Morgan Alerian MLP Index ETN

Defiance Israel Bond ETF

Capital Link Global Fintech Leaders ETF

Teucrium AiLA Long-Short Base Metals Strategy ETF

Invesco QQQ

SPDR S&P 500 ETF Trust

PGIM US Large-Cap Buffer 12 ETF - December

PGIM US Large-Cap Buffer 12 ETF - November

PGIM US Large-Cap Buffer 20 ETF - November

PGIM US Large-Cap Buffer 20 ETF - December

FT Vest Nasdaq-100 Moderate Buffer ETF - May

FT Vest US Equity Enhance & Moderate Buffer ETF - May

The week ended May 24, 2024 saw the rollout of 17 new ETFs, including six defined outcome funds. The total count was the highest it's been in several weeks, with launches slowing notably in the weeks around the Easter and Passover holidays.

This Week in ETFs: Roster of 17 New ETFs Includes 6 Buffer Funds

Global obesity rates have nearly tripled since 1975, per WHO and Goldman Sachs. The growing usage of GLP-1 drugs in weight management now makes the industry a thriving one.

Play These New ETFs to Tap Lucrative Weight Loss Drug Market

OZEM provides exposure to the rapidly growing weight loss management market, which is expected to reach $100 billion by 2030. NEW YORK , May 21, 2024 /PRNewswire/ -- Roundhill Investments, an ETF sponsor focused on innovative financial products, is pleased to announce the launch of the Roundhill GLP-1 & Weight Loss ETF (OZEM), which began trading on Nasdaq today.

Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM)

News for Roundhill GLP-1 & Weight Loss ETF ETF (OZEM)